25-APR-2024 6:10

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY ADMIN CCADMIN ACCR.
GOAL		 R
E
G		 O
P
E
N		 ARM TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol SURV   817 1 T 0 Screening 329 18 6 0 0 0
              329 18 6 0 0 0
 
        2 T 1 Carvedilol 74 8 2 0 0 0
            2 No prophylaxis 81 10 6 0 0 0
            3 Observation 155 0 0 0 0 0
              310 18 8 0 0 0
 
S1703-Met Breast, STM-monitoring v Usual Care CCD SXQOL 739 1 Y 0 Screening 491 71 41 15 2 2
              491 71 41 15 2 2
 
        2 Y 1 Control (Usual Care) 165 29 13 8 2 0
            2 Intervention (STMDDM) 168 31 17 10 3 2
              333 60 30 18 5 2
 
S1706-Breast, Inflammatory, RT +/- Olaparib BREAST SXQOL 300 1 Y 1 Olaparib + RT 75 11 5 4 1 0
            2 RT 78 11 9 4 1 0
              153 22 14 8 2 0
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum GU SXQOL 1273 1 Y 0 Induction SST 790 119 63 32 9 1
              790 119 63 32 9 1
 
        2 Y 1 Standard Systemic Therapy Only 277 39 16 7 2 0
            2 SST + Surgery/RT 279 41 19 9 3 0
              556 80 35 16 5 0
 
S1803-MM, Maintenance, Len vs Len/Dara MMYEL SXQOL 1420 1 Y 0 Screening 1219 78 78 58 21 3
              1219 78 78 58 21 3
 
        2 Y 1 Lenalidomide 558 43 31 22 9 3
            2 Lenalidomide + Daratumumab 553 45 36 31 11 2
              1111 88 67 53 20 5
 
        3 Y 3 Continue Lenalidomide 27 16 5 2 1 0
            4 Stop Lenalidomide 27 16 5 2 0 0
            5 Continue Lenalidomide + Dara 63 30 13 8 4 1
            6 Stop Lenalidomide + Dara 62 30 14 5 3 1
              179 92 37 17 8 2
 
S1823-GCT, Obs. Cohort, miRNA371 PREV   956 1 Y 1 Observation Arm 940 226 102 56 20 1
              940 226 102 56 20 1
 
S1827-SCLC, MRI Surveillance +/- PCI LUNG SXQOL 668 1 Y 1 PCI + MRI brain surveillance 106 36 13 10 1 0
            2 MRI brain surveillance 107 37 17 14 3 0
              213 73 30 24 4 0
 
S1904-Breast, Decision making for chemoprevention PREV   415 1 Y 1 Standard Education Materials 175 51 33 16 5 0
            2 Support Tools + Standard Education Materials 223 68 40 19 5 1
              398 119 73 35 10 1
 
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship CCD   326 1 Y 1 Financial Navigation 114 75 51 25 9 1
            2 Control 113 74 49 21 6 0
              227 149 100 46 15 1
 
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo LUNG SXQOL 480 1 Y 1 Atezolizumab and SBRT 178 77 44 26 6 0
            2 SBRT 172 73 36 17 4 0
              350 150 80 43 10 0
 
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP LYMPH SXQOL 422 1 Y 1 CC-486 + R-miniCHOP 49 22 13 5 3 1
            2 R-miniCHOP 47 24 11 5 0 0
              96 46 24 10 3 1
 
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O LEUK SXQOL 247 1 Y 1 Delayed V-O 35 12 7 3 3 0
            2 Early V-O 65 24 12 7 2 1
              100 36 19 10 5 1
 
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed SXQOL   540 1 Y 1 Active Symptom Monitoring + Patient Education 138 135 84 48 12 0
            2 Patient Education 139 137 84 49 13 2
              277 272 168 97 25 2
 
S2013-I-CHECKIT: ICI toxicity risk prediction study SXQOL   2062 1 Y 1 Observation Arm 2043 1085 537 287 109 22
              2043 1085 537 287 109 22
 
S2108CD-Genomic Tumor Board vs Usual Practice CCD   1182 1 Y 1 Usual Practice 426 277 127 60 11 1
            2 EGTB Intervention 526 409 181 77 17 3
              952 686 308 137 28 4
 
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes SXQOL   777 1 Y 1 Cryocompression 42 42 30 18 7 0
            2 Continuous Compression 43 43 30 17 7 0
            3 Low Cyclic Compression 42 42 28 16 4 0
              127 127 88 51 18 0
 
S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva BREAST SXQOL 960 1 Y 1 Tissue for MammaPrint testing 50 50 50 43 17 0
              50 50 50 43 17 0
 
        2 Y 2 SOC Chemotherapy 4 4 4 4 1 0
            3 SOC Chemotherapy + Durvalumab 4 4 4 4 1 0
              8 8 8 8 2 0
 
S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa LYMPH SXQOL 227 1 Y 1 Tazemetostat (Arm 1) Dose Level 1 3 3 3 2 2 1
            4 Zanubrutinib (Arm 3) Dose Level 1 10 10 8 6 4 1
              13 13 11 8 6 2
 
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D MMYEL SXQOL 510 1 Y 1 VRD-R 7 7 6 3 2 0
            2 DRD-R 7 7 7 3 1 0
            3 DRD-DR 6 6 6 4 1 1
              20 20 19 10 4 1
 
S2212-Breast, TNBC, Neoadj Chemo + Pembro BREAST SXQOL 2400 1 Y 1 Carbo + Paclitaxel + Pembro -> AC + Pembro 58 58 55 39 17 3
            2 Carbo + Docetaxel + Pembro 54 54 50 33 10 1
              112 112 105 72 27 4
 
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT MMYEL SXQOL 338 1 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
        2 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
        3 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib BREAST SXQOL   1 E   42 18 6 2 1 0
              42 18 6 2 1 0
 
A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab BREAST SXQOL   1 E   5 5 3 1 0 0
              5 5 3 1 0 0
 
A021806-Pancreas, Perioperative vs Adjuvant Chemo GI SXQOL   0 E   35 10 4 1 0 0
              35 10 4 1 0 0
 
        1 E   29 9 4 1 0 0
              29 9 4 1 0 0
 
A022001-PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM GI SXQOL   1 E   2 2 1 0 0 0
              2 2 1 0 0 0
 
A022004-Colon, Stg II-III, Encor+Cetux vs SOC GI SXQOL   0 E   3 3 3 3 1 0
              3 3 3 3 1 0
 
        1 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo GU SXQOL   1 E   126 20 13 8 4 0
              126 20 13 8 4 0
 
        2 E   84 13 4 4 1 0
              84 13 4 4 1 0
 
A032103-Urothelial, All Stg, MRD-Based Adj Tx GU SXQOL   0 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
        1 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub LYMPH SXQOL   1 E   5 5 5 4 2 2
              5 5 5 4 2 2
 
        2 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO LUNG SXQOL   1 E   75 19 8 5 2 0
              75 19 8 5 2 0
 
A211901-Cancer survivors who smoke, txt cessation SURV     1 E   5 5 4 2 1 1
              5 5 4 2 1 1
 
ACCL16N1-Guideline Consistent Treatment AYA ALL CCD     1 T   54 0 0 0 0 0
              54 0 0 0 0 0
 
AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy LYMPH SXQOL   1 E   17 17 12 5 3 0
              17 17 12 5 3 0
 
        2 E   13 13 12 4 1 0
              13 13 12 4 1 0
 
CCTGHN11-HN, All Stg, Guided Elec Contra Neck Tx OTHER SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
        2 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) MMYEL SXQOL   0 E   46 22 9 2 0 0
              46 22 9 2 0 0
 
        1 E   35 17 8 3 1 0
              35 17 8 3 1 0
 
        2 E   17 10 5 2 1 0
              17 10 5 2 1 0
 
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT BREAST SXQOL   1 E   29 15 8 7 3 0
              29 15 8 7 3 0
 
        2 E   28 15 7 6 3 0
              28 15 7 6 3 0
 
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction SXQOL OTHER   1 E   7 4 2 1 0 0
              7 4 2 1 0 0
 
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide GU SXQOL   1 E   13 7 4 3 1 0
              13 7 4 3 1 0
 
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx GU SXQOL   1 E   9 8 6 1 0 0
              9 8 6 1 0 0
 
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo LUNG SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
A031801-GU, mRCC, Cabozantinib +/- Radium-223 GU SXQOL   1 E   14 5 3 1 0 0
              14 5 3 1 0 0
 
A082002-Lung, Adv, Systemic Tx +/- SBRT LUNG SXQOL   1 E   4 1 1 0 0 0
              4 1 1 0 0 0
 
A191901-Brst, Text/Motivational Intervention ET Adher CCD     1 E   39 0 0 0 0 0
              39 0 0 0 0 0
 
A212102-Blind Ref Set for Multicancer Early Detection PREV     1 E   94 62 37 25 6 2
              94 62 37 25 6 2
 
A221805-Colorectal, Duloxetine for Oxaliplatin CIPN SXQOL     1 E   8 0 0 0 0 0
              8 0 0 0 0 0
 
        2 E   6 0 0 0 0 0
              6 0 0 0 0 0
 
A222004-Mult, Olanza vs Megestrol for Anorexia SXQOL     1 E   3 1 1 0 0 0
              3 1 1 0 0 0
 
A231602C-Blood Cancer, Assess Financial Difficulty CCD     1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
ACCL1931-Leuk, All Stg, Levocarnitine Prophylaxis SXQOL     1 E   2 2 2 2 2 1
              2 2 2 2 2 1
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL   1 E   2 1 0 0 0 0
              2 1 0 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo OTHER SXQOL   1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
EA2182-Anal, Erly, DECREASE GI SXQOL   0 E   12 6 0 0 0 0
              12 6 0 0 0 0
 
        1 E   13 6 0 0 0 0
              13 6 0 0 0 0
 
EA2185-Panc, Impact of Panc Cyst Surveillance PREV SXQOL   1 E   19 7 3 1 0 0
              19 7 3 1 0 0
 
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL   1 E   12 2 0 0 0 0
              12 2 0 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
EA8184-Pros, Dbl Blind GTC vs Placebo PREV SXQOL   0 E   14 11 6 3 2 2
              14 11 6 3 2 2
 
        1 E   4 4 1 0 0 0
              4 4 1 0 0 0
 
EA8191-Pros, Local vs Systemic Thrpy GU SXQOL   0 E   29 13 7 2 1 0
              29 13 7 2 1 0
 
        1 E   29 13 7 2 1 0
              29 13 7 2 1 0
 
EA8212-Blad, NMIBC, BRIDGE GU SXQOL   1 E   104 89 54 34 11 1
              104 89 54 34 11 1
 
EAA173-MYEL, SMM, Rd +/- Daratumumab MMYEL SXQOL   0 E   63 17 10 6 3 2
              63 17 10 6 3 2
 
        1 E   27 5 3 1 1 1
              27 5 3 1 1 1
 
EAQ202-Improving AYA PROs in EA Trials SXQOL     1 E   43 0 0 0 0 0
              43 0 0 0 0 0
 
NHLBIMDS-LEUK, National MDS Study CCD     1 E   247 41 23 15 7 1
              247 41 23 15 7 1
 
NRGBN003-Mening, Grd II, Observation vs Irradiation OTHER SXQOL   1 E   5 0 0 0 0 0
              5 0 0 0 0 0
 
        2 E   3 0 0 0 0 0
              3 0 0 0 0 0
 
NRGBN011-Brain, Lomustine + Temo vs Temo OTHER SXQOL   1 E   15 10 4 0 0 0
              15 10 4 0 0 0
 
        2 E   4 2 0 0 0 0
              4 2 0 0 0 0
 
NRGBN012-Brain, Pre- vs Post-Op Stereotactic Radiosurg OTHER SXQOL   1 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
NRGBR007-Breast, Stg I, De-Escalation of Breast RT BREAST SXQOL   1 E   8 5 2 0 0 0
              8 5 2 0 0 0
 
        2 E   8 5 2 0 0 0
              8 5 2 0 0 0
 
NRGBR009-Breast, EarlyStg, Adjuvant Chemo BREAST SXQOL   1 E   3 3 3 3 0 0
              3 3 3 3 0 0
 
        2 E   3 3 3 3 0 0
              3 3 3 3 0 0
 
NRGCC005-Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs PREV     1 E   4 4 4 3 1 0
              4 4 4 3 1 0
 
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO PREV SXQOL   1 E   9 4 3 1 0 0
              9 4 3 1 0 0
 
NRGCC011-Breast, Survivors, Cog Training SXQOL     0 E   1 1 1 1 1 0
              1 1 1 1 1 0
 
        1 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy GI SXQOL   1 Y   15 0 0 0 0 0
              15 0 0 0 0 0
 
NRGGU009-Pros, PREDICT-RT GU SXQOL   1 E   49 32 18 8 5 0
              49 32 18 8 5 0
 
        2 E   46 32 18 7 4 0
              46 32 18 7 4 0
 
NRGGU010-Pros, Parallel De-Intens & Intens Trials GU SXQOL   1 E   34 21 11 4 2 0
              34 21 11 4 2 0
 
        2 E   31 19 9 3 1 0
              31 19 9 3 1 0
 
NRGHN005-HN, early stg P16-pos, randomize de-intensifi OTHER SXQOL   1 E   8 1 0 0 0 0
              8 1 0 0 0 0
 
NRGHN006-HN, Erly Stg, Biopsy vs Dissection OTHER SXQOL   1 E   1 0 0 0 0 0
              1 0 0 0 0 0
 
        2 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN OTHER SXQOL   1 E   14 9 6 3 1 0
              14 9 6 3 1 0
 
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux OTHER SXQOL   1 E   6 1 0 0 0 0
              6 1 0 0 0 0
 
        2 E   5 1 0 0 0 0
              5 1 0 0 0 0
 

25-APR-2024 6:10

Cancer Coltrol Open Studies with No Registrations

Study Admin CCAdmin Registration/Phase Open Date
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT MMYEL SXQOL 1 Induction 01-Dec-23
  MMYEL SXQOL 2 Randomization 01-Dec-23
  MMYEL SXQOL 3 Maintenance 01-Dec-23
A022004 Colon, Stg II-III, Encor+Cetux vs SOC GI SXQOL 1 Registration 30-May-23
A032103 Urothelial, All Stg, MRD-Based Adj Tx GU SXQOL 1 Registration 09-Jan-24
  GU SXQOL 2 Re-Registration 09-Jan-24
ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis SXQOL   2 Callback 14-Aug-23
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL 2 Late Randomization Callback 08-May-17
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL 2 Randomization2 08-Sep-17
NRGCC011 Breast, Survivors, Cog Training SXQOL   1 Randomization 02-Feb-24